UnitedHealth Stock Analysis: Value, Medicare Advantage, and Future Strategy

UnitedHealth's Valuation Concerns

• 💡 John Ransom from Raymond James suggests there are cheaper ways to invest in a Medicare Advantage recovery, citing Humana at a 6x P/E and CVS at an 8x P/E.
• ⚠️ Even if UnitedHealth (UNH) reaches $30 per share in earnings in a few years, its stock is considered 30-40% more expensive than similar opportunities.
• 📉 While UNH's stock has fallen, the buy-side's starting earnings estimate of $18-$20 per share is seen as potentially too high for significant future clawbacks.

Alternative Investment Opportunities

• 🎯 Jeff Jonas from Gabelli agrees on valuation concerns and prefers other insurers like Sigma (less government exposure) or Elevance (trading under 10x earnings).
• 📊 Both experts acknowledge UNH's strong franchise and diversification, but current valuation and potential risks overshadow these positives.

Strategic and Operational Considerations

• 🚀 The company has an opportunity to reset its guide and strategy next week, which is a key focus.
• 🧩 A significant point of interest is the Optum Health business, a $60 billion venture where UNH takes on risk for itself and competitors.
• ⚠️ The sustainability of this risk-taking model is questioned, especially if Medicare Advantage margins are now only 1-2%, drawing parallels to Wells Fargo not buying loans from JP Morgan at a loss.

Investigation and Future Impact

• 🔍 The ongoing investigation by the Wall Street Journal is a significant factor, with the company initially unaware of it.
• 📈 The ultimate impact may not be a fine, but rather changes in behavior such as less aggressive coding or tougher prior authorizations.
• ⚠️ Even small shifts in these areas could significantly impact earnings for a business with 1-2% margins.